Retromer Therapeutics

Year Invested/Status: 2020/Active
Motivation: Despite multiple attempts to curtail progression of neurodegenerative diseases, few safe & efficacious therapeutics have come to market, underscoring the importance of accelerating novel approaches to a disease modifying therapeutic.

Lead Program(s): Retromer Therapeutics is pioneering a new class of therapeutics to treat neurodegenerative diseases by restoring the function of the endolysosmal trafficking system with preclinical programs in neurodegenerative diseases.

Pre-Clinical

Phase 1

Phase 2

Phase 3

Learn more in the pipeline
© 2022 CinRx Pharma. All Rights Reserved.
844-531-1834 | [email protected]

SITE PAGES

CINRX IN THE NEWS

FOLLOW US

Linkedin-in Twitter
844-531-1834 | [email protected]
Linkedin-in Twitter
© 2022 CinRx Pharma. All Rights Reserved.

INVESTOR INQUIRIES

CAREER INQUIRIES

GENERAL INQUIRIES